Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 10/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175143 | 0.84 | DHODH (0.72) | DHODHALDH1A1KDM4ERAB9A | |
| SCHEMBL4793832 | 0.79 | DHODH (0.65) | DHODHHDAC1HDAC8HDAC6KDM4E | |
| SCHEMBL17896671 | 0.78 | DHODH (0.64) | DHODHALDH1A1KDM4E | |
| SCHEMBL505230 | 0.77 | DHODH (0.63) | DHODHHDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL1104852 | 0.77 | DHODH (0.61) | DHODHADORA2AADORA2BALDH1A1KDM4E | |
| SCHEMBL22453145 | 0.75 | DHODH (0.60) | DHODHADORA2AADORA2BALDH1A1KDM4E | |
| SCHEMBL1078934 | 0.74 | DHODH (0.59) | DHODHALDH1A1KDM4ETP53RAB9A | |
| SCHEMBL10175108 | 0.73 | DHODH (0.57) | DHODHADORA2AADORA2BALDH1A1KDM4E | |
| SCHEMBL29281090 | 0.72 | DHODH (0.57) | DHODHALDH1A1KDM4ENPC1TP53 | |
| SCHEMBL9611665 | 0.72 | ALDH1A1 (0.75) | DHODHHDAC1HDAC8HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414328-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-20150011774-A1 | PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
| EP-2414328-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| EP-1685126-A2 | PREPARATION OF CANDESARTAN CILEXETIL | Teva Pharmaceutical Industries Limited (IL) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005037821-A2 | PREPARATION OF CANDESARTAN CILEXETIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-04-28 | — | — | WO | disclosed |
| US-6686383-B2 | TREATMENT OF DIABETIC NEPHROPATHY WITH A BIPHENYL-4-YL)ALKYL-1H-BENZIMIDAZOLE COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2004-02-03 | — | — | US | disclosed |
| US-20020022587-A1 | Methods for effecting neuroprotection | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-02-21 | — | — | US | disclosed |
| WO-2001072335-A2 | METHODS FOR EFFECTING NEUROPROTECTION USING A POTASSIUM CHANNEL MODULATOR | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, FH, DPYD | DHODH 1/4885HDAC1 333/4885HDAC8 1363/4885 |
| US-20150011774-A1 | PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | REN, AGTR2, CYP4A11 | DHODH 135/4885HDAC1 4027/4885HDAC8 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.